European approval for in-licensed Menarini antibiotic

12 December 2018

Just two months after acquiring exclusive rights to commercialize meropenem/vaborbactam in Europe and parts of Asia, family-controlled Italian drugmaker Menarini Group has announced that the antibiotic has been approved by the European Commission.

Marketed as Vabomere in the USA, meropenem/vaborbactam was developed by US antibiotics developer Melinta Therapeutics (Nasdaq: MLNT). It was in-licensed by Menarini along with two other assets in a deal announced in October.

Meropenem/vaborbactam has been approved in Europe for clinical use in adult patients with difficult-to-treat infections, making it the first combination of a carbapenem and a beta-lactamase inhibitor to gain marketing authorization in the continent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK